The Role of Cell Cycle Arrest Biomarkers for Predicting Acute Kidney Injury in Critically Ill COVID-19 Patients: A Multicenter, Observational Study.

"Dr. Ostermann received research funding from BioMérieux and Baxter. Dr. Garcia received funding from Edwards Lifesciences. Dr. Cano disclosed work for hire. Dr. Broch-Porcar disclosed that she participated in a lecture in Nephroweek with economical compensation from BioMereiux. Drs. de la Peña, Meersch, and Zarbock received funding from Baxter. Dr. Brivio received funding from Jafron and Bbraun. Dr. de Rosa received lectures fees from ESTOR SpA. Drs. Kellum’s and Zarbock’s institutions received funding from BioMereiux. Drs. Kellum, Meersch, and Zarbock received funding from BioMereiux. Dr. Meersch received funding from FMC and Baxter. Dr. Gerss received honoraria from TESARO, QUIRIS Healthcare, Ecker+Ecker, Dr August Wolff, Roche, University Clinics Schleswig-Holstein, and RWTH Aachen University. Dr. von Groote was supported by a rotational position of KFO 342, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)–ZA428/18-1. Dr. Zarbock’s institution received funding from DFG, Baxter, and Fresenius; he received funding from AM Pharma, Novartis, Alexion, Bayer, Guard Therapeutics, Paion, and Fresenius as well as independent research grants from the German Research Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest."

"We would like to thank the study nurses at all participating centers for patient recruitment and data entry and the staff in the participating ICUs for supporting the study. Also, we acknowledge the support by the Open Access Publication Fund of the University of Münster, Germany. We would like to thank the study nurses at all participating centers for patient recruitment and data entry and the staff in the participating ICUs for supporting the study. Also, we acknowledge the support by the Open Access Publication Fund of the University of Münster, Germany. The study was supported by the German Research Foundation (KFO342-1, ZA428/18-1, and ZA428/21-1 to Dr. Zarbock and ME5413/1-1 to Dr. Meersch) and an unrestricted research grant from BioMerieux. Dr. Ostermann received research funding from BioMérieux and Baxter. Dr. Garcia received funding from Edwards Lifesciences. Dr. Cano disclosed work for hire. Dr. Broch-Porcar disclosed that she participated in a lecture in Nephroweek with economical compensation from BioMereiux. Drs. de la Peña, Meersch, and Zarbock received funding from Baxter. Dr. Brivio received funding from Jafron and Bbraun. Dr. de Rosa received lectures fees from ESTOR SpA. Drs. Kellum’s and Zarbock’s institutions received funding from BioMereiux. Drs. Kellum, Meersch, and Zarbock received funding from BioMereiux. Dr. Meersch received funding from FMC and Baxter. Dr. Gerss received honoraria from TESARO, QUIRIS Healthcare, Ecker+Ecker, Dr August Wolff, Roche, University Clinics Schleswig-Holstein, and RWTH Aachen University. Dr. von Groote was supported by a rotational position of KFO 342, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)–ZA428/18-1. Dr. Zarbock’s institution received funding from DFG, Baxter, and Fresenius; he received funding from AM Pharma, Novartis, Alexion, Bayer, Guard Therapeutics, Paion, and Fresenius as well as independent research grants from the German Research Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest."

"We conducted a multicenter, multinational, observational study in 12 centers across Europe and the United Kingdom. Institutional review board approval was obtained from the Research Ethics Committee of the Chamber of Physicians Westfalen-Lippe and the Westfalian Wilhelms University Muenster (2020-265-f-S) as well as the corresponding institutional review boards of all participating centers. The study was registered prior to patient enrollment at ClinicalTrials.gov (NCT04406688, date of registration May 28, 2020). In the United Kingdom, it was approved as a National Institute for Health and Care Research (NIHR) portfolio study (NIHR Central Portfolio Management System Identificator 45824). The study was conducted in accordance with the Declaration of Helsinki (Version Fortaleza, 2013). Written informed consent was obtained from all participating patients or representatives according to local requirements and legislation. Trial registration: The study was registered prior to patient enrollment at ClinicalTrials.gov (NCT04406688, date of registration May 28, 2020)."